Covaxin out of clinical trial mode, granted restricted emergency use authorisation
The Centre on Thursday said Bharat Biotech's indigenously developed Covaxin is out of the "clinical trial mode" and that it has now been granted the regular restricted emergency use authorisation just like Covishield manufactured by Serum Institute. NITI Aayog member (Health) Dr V K Paul said Covaxin and Covishield have the same licensure status now.
You Might Like
💡 newsR Knowledge: Other News Mentions
Use entire national capacity to step up Covid vaccine production, PM tells officialsThe PM’s directive came at a review meeting on the Covid situation on Saturday a day after he had overseen an assessment of oxygen supplies and production and..
Covaxin production to be increased to 100 million doses per month by September 2021: CentreUnion health minister Harsh Vardhan said financial support is being provided to four manufacturers to expand Covaxin vaccine production.
India to increase Covaxin production to 100 million doses per month by SeptemberThe Union government on Friday said it will amp up the production of the indigenously developed Covaxin vaccine to 100 million doses per month by September. As..
Mumbai's Haffkine Institute gets Centre's nod to produce Covaxin
Credit: ANI Duration: 01:14Published
‘Covaxin, Covishield both work against Covid's UK strain’Both Covaxin and Covishield — the two vaccines against Covid in use in India — are effective against the UK variant, which is one the two prevailing..
Vietnam envoy takes first dose of Indian COVID-19 vaccine CovaxinThe Vietnamese envoy joins other envoys in getting vaccinated. Earlier this month, Australian envoy got vaccinated using Covishield vaccine.
COVID-19 news: India gets third vaccine as Russia's Sputnik V gets nod for emergency useThis is the third COVID-19 vaccine approved by the Subject Expert Committee (SEC) after Covishield and Covaxin.
Kerala dance trend: Vaccines shake a leg to Rasputin | Oneindia News
Credit: Oneindia Duration: 01:06Published
European Medicines Agency issues post-vax adverse-event alert for medicsThe safety committee of the European Medicines Agency (EMA) has asked those receiving the AstraZeneca vaccine (called Covishield in India) and medical..
Even as Covid vaccine demand rises, firms may take some weeks to up productionIndications are that India’s vaccine production is expected to be limited for a few more weeks though a step-up is expected as Serum Institute of India and..
India gifts one lakh doses of COVID-19 vaccine to Nepal Army
Credit: ANI Duration: 01:23Published
India-made vaccine to be dispatched for Denmark
Credit: ANI Duration: 01:25Published
Watch: UK PM Boris Johnson gets his first jab of AstraZeneca Covid-19 vaccine
Credit: HT Digital Content Duration: 02:03Published
Remdesivir for those who are hospitalized, not to be procured from chemist shops: Niti Aayog
Credit: ANI Duration: 02:26Published
‘Doses approved by US regulators…’: Centre on vaccines, Remdesivir use | Covid
Credit: HT Digital Content Duration: 06:23Published
Remdesivir 'not for home use', Centre says amid rise in demandAddressing a media briefing on Tuesday, Niti Aayog member Dr V K Paul said Remdesivir is "only for those who require hospitalisation and oxygen. That is the..
No vaccine shortage in country: NITI Aayog
Credit: ANI Duration: 01:26Published
Related videos from verified sources
Related news from verified sources